Physician profile
Robert Koblin
NPI 1851506083
$3,302.98
in general payments reported to CMS, 2019-2025
34 companies · $49.24 in 2025
The $49.24 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $245 · 2021: $569 · 2022: $528 · 2023: $585 · 2024: $310 · 2025: $49.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $783.06 | 2019-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $343.27 | 2019-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $318.72 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $228.73 | 2019-2023 | Farxiga, Breztri, Brilinta |
| Pfizer INC. | $213.71 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.89 | 2019-2023 | Xifaxan |
| Biosense Webster, INC. | $125.17 | 2022 | |
| Boston Scientific Corporation | $116.01 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Regeneron Healthcare Solutions, INC. | $108.80 | 2019 | |
| Lilly USA, LLC | $103.70 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $77.04 | 2019-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $73.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.59 | 2022 | |
| Bardy Diagnostics, INC. | $50.14 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.16 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $46.73 | 2023-2024 | Amvuttra |
| Heartflow, INC. | $44.14 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $43.17 | 2019-2024 | Delstrigo, Pifeltro |
| Sanofi-Aventis U.S. LLC | $39.79 | 2019 | |
| Glaxosmithkline, LLC. | $38.60 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $31.59 | 2023 | Arcalyst |
| Viiv Healthcare Company | $28.88 | 2024 | Apretude |
| Abbvie INC. | $28.24 | 2022 | |
| Eisai INC. | $24.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.94 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.71 | 2023 | Jardiance, Tradjenta, Synjardy |
| Esperion Therapeutics, INC. | $22.83 | 2021 | |
| Allergan, INC. | $21.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.21 | 2019 | |
| Genentech USA, INC. | $17.81 | 2019 | |
| Amarin Pharma, INC. | $17.47 | 2019 | |
| Janssen Scientific Affairs, LLC | $16.99 | 2021 | |
| Philips North America LLC | $14.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Koblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.